Kirin – Investment in Nightingale Health

We advised Kirin Holdings Company (Tokyo, Japan) in their co-investment with Mitsui & Co., Ltd. in, and strategic partnership with, Finnish blood-testing company Nightingale Health Oy.

Nightingale Health Ltd., is a market leader in advanced blood-testing for preventative health solutions. The strategic partnership is formed to launch Nightingale’s blood-testing services in Japan, as well as to develop novel wellness products. The aim of this initiative is to help people to stay healthy by leveraging the globally unique biomarker information provided by Nightingale’s blood-test.

Kirin is a global, multi-industry food and beverages company headquartered in Tokyo. Kirin manufactures and sells alcohol and non-alcohol beverages globally through its underlying companies such as Kirin Brewery (Japan), Kirin Beverage (Japan), Lion (Australia), and Myanmar Brewery (Myanmar), as well as engages in pharmaceutical and bio-chemical businesses through Kyowa Kirin and Kyowa Hakko Bio.

Mitsui is one of the most diversified and comprehensive trading, investment and service enterprises in the world, with 139 offices in 66 countries as of Apr, 2019. Utilising its global operating locations, network and information resources, Mitsui is multilaterally pursuing business that ranges from product sales, worldwide logistics and financing, through to the development of major international infrastructure and other projects in the following fields: Iron & Steel Products, Mineral & Metal Resources, Infrastructure Projects, Mobility, Chemicals, Energy, Food, Food & Retail Management, Healthcare & Service, IT & Communication Business, Corporate Development Business.